Haring-Layton MarDee 4
4 · Dare Bioscience, Inc. · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Dare Bioscience (DARE) CAO MarDee Haring-Layton Receives Award
What Happened MarDee Haring-Layton, Chief Accounting Officer of Dare Bioscience (DARE), received a grant of 49,000 derivative shares (stock-option award) on January 30, 2026. The reported acquisition price is $0.00 (the award was granted, not purchased), so there was no cash outlay recorded by the insider at grant.
Key Details
- Transaction date: 2026-01-30; filing date: 2026-02-02 (Form 4 accession 0001535596-26-000002).
- Amount: 49,000 derivative securities (stock-option award); reported price: $0.00.
- Vesting: 48 equal monthly installments beginning one month after the grant date, subject to continued service (per footnote).
- Shares owned after transaction: not specified in the provided summary of the filing.
- No sale or exercise occurred — this is an award/grant of derivative securities.
Context This was a compensatory award of derivative securities (stock options) to an executive, which typically vests over time and does not represent an immediate market buy or sell. Because the award vests monthly over four years, its value to the insider is tied to continued service and future company performance; the filing shows no immediate cash transaction.
Insider Transaction Report
- Award
Employee Stock Option (right to buy)
[F1]2026-01-30+49,000→ 49,000 totalExercise: $1.81Exp: 2036-01-30→ Common stock (49,000 underlying)
Footnotes (1)
- [F1]This stock option vests and becomes exercisable in 48 equal monthly installments commencing on the one-month anniversary of the grant date, subject to the reporting person's continuous service to the issuer.